Drug Profile
INT 301
Alternative Names: INT-301Latest Information Update: 26 Feb 2024
Price :
$50
*
At a glance
- Originator Intrommune Therapeutics
- Class Allergens; Allergy immunotherapies; Food allergy immunotherapies
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Peanut hypersensitivity
Most Recent Events
- 22 Feb 2024 Efficacy data from the phase Ib OMEGA trial in Peanut hypersensitivity released by Intrommune Therapeutics
- 09 Nov 2023 Updated adverse events data from the phase Ib OMEGA trial in Peanut hypersensitivity presented at the Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI-2023)
- 25 Jul 2023 Adverse events data from a phase Ib OMEGA trial in peanut hypersensitivity released by Intrommune Therapeutics